1. Home
  2. NG vs BLLN Comparison

NG vs BLLN Comparison

Compare NG & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novagold Resources Inc.

NG

Novagold Resources Inc.

HOLD

Current Price

$9.01

Market Cap

3.7B

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$78.74

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NG
BLLN
Founded
1984
2016
Country
Canada
United States
Employees
N/A
713
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.5B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
NG
BLLN
Price
$9.01
$78.74
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$11.90
$126.71
AVG Volume (30 Days)
3.7M
311.5K
Earning Date
04-01-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$45.89
Revenue Next Year
N/A
$30.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.26
$61.96
52 Week High
$14.40
$138.70

Technical Indicators

Market Signals
Indicator
NG
BLLN
Relative Strength Index (RSI) 45.86 53.54
Support Level $7.85 $63.98
Resistance Level $10.61 $83.20
Average True Range (ATR) 0.66 5.71
MACD 0.04 1.39
Stochastic Oscillator 46.78 68.67

Price Performance

Historical Comparison
NG
BLLN

About NG Novagold Resources Inc.

Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: